ADVERTISEMENT
ADVERTISEMENT

Cardiology

Edited by: James Kling B.M. Psaty, S.R. Heckert, T.D. Koepsell, D.S. Siscovick, T.E. Raghunathan, N.S. Weiss, F.R. Rosendaal, R.N. Lemaitre, N.L. Smith, P.W. Wahl, E.H. Wagner, C.D. Furberg, "The risk of myocardial infarction associated with antihypertensive drug therapies," JAMA-Journal of the American Medical Association, 274:620-5, 1995. (Cited in nearly 140 papers through June 1997) Comments by Bruce M. Psaty, University of Washington School of Medicine. RAISING A QUESTION: Bruce Psaty's

The Scientist Staff

Edited by: James Kling
B.M. Psaty, S.R. Heckert, T.D. Koepsell, D.S. Siscovick, T.E. Raghunathan, N.S. Weiss, F.R. Rosendaal, R.N. Lemaitre, N.L. Smith, P.W. Wahl, E.H. Wagner, C.D. Furberg, "The risk of myocardial infarction associated with antihypertensive drug therapies," JAMA-Journal of the American Medical Association, 274:620-5, 1995. (Cited in nearly 140 papers through June 1997)

Comments by Bruce M. Psaty, University of Washington School of Medicine.


RAISING A QUESTION: Bruce Psaty's study looked at antihypertensive medications that his team felt had been insufficiently evaluated.
In the 1980s and 1990s, scientists evaluating the utility of calcium channel blockers (CCBs) in preventing heart disease in patients with high blood pressure (hypertension) have looked for evidence that the agents lowered blood pressure. "But since physicians treat high blood pressure to prevent devastating complications such as heart attacks and strokes, new therapies should ideally be evaluated in large, long-term clinical trials that measure...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT